Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
You currently have no recent searches
University of Massachusetts Medical School
The replication of retroviruses is dependent upon their ability to commandeer cellular factors at various stages in the replication cycle. Research over the past several years however, has revealed the presence of “cellular restrictions” that potently antagonize the replication of viruses such as HIV-1. For example, the Apobec 3 proteins are cytidine deaminases that compromise the formation and integrity of viral cDNA while Bst2/tetherin prevents detachment of budding viruses from the surface of the infected cell. In order to counteract these restrictions, primate lentiviruses have evolved accessory proteins: the Vif protein targets Apobec 3 for proteasomal destruction while Vpu mislocalizes Bst2/tetherin away from sites of virus budding. We have recently obtained evidence for novel restrictions that are expressed in cells of macrophage lineage. One restriction potently antagonizes retrovirus replication including the lentiviruses, HIV-1/2 and SIV as well as the gamma retrovirus, MLV. We have evidence that this restriction is counteracted by the viral accessory proteins Vpx/Vpr. These proteins commandeer a damaged DNA response protein (DDB1) to target the restriction to the proteasome. We have further obtained evidence that this restriction dictates the cell cycle dependence of retrovirus infection and is the obstacle to monocyte infection by retroviruses. Therefore when the restriction is neutralized, macrophages, which are normally refractory to MLV infection, are rendered permissive to MLV transduction. The second restriction antagonizes virus egress and is counteracted by the Vpu proteins of HIV-1/SIV. Given our increasing understanding of the function of the viral accessory proteins, they remain highly attractive targets for therapeutic intervention in HIV/AIDS.
© 2011 Lippincott Williams & Wilkins, Inc.
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at JAIDS Journal of Acquired Immune Deficiency Syndromes.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection
Article Level Metrics